Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2016 Financial Results and Provides Corporate Update

Go back to Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2016 Financial Results and Provides Corporate Update

Intra-Cellular Therapies (ITCI) Tops Q4 EPS by 13c

March 1, 2017 7:12 AM EST

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q4 EPS of ($0.64), $0.13 better than the analyst estimate of ($0.77). Revenue for the quarter came in at $97.9 thousand, versus $30.66 thousand reported last year.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

... More